Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 74.3%

Neg 74.3% Neu 0% Pos 0%

Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.